US2008175884A1PendingUtilityA1

Medical Devices Containing Rapamycin Analogs

64
Assignee: ABBOTT CARDIOVASCULAR SYSTEMSPriority: Sep 10, 2001Filed: Mar 3, 2008Published: Jul 24, 2008
Est. expirySep 10, 2021(expired)· nominal 20-yr term from priority
A61L 2300/604A61L 2300/606C07D 498/18A61P 37/02A61L 2300/416A61L 27/34A61P 37/06A61P 31/10A61L 2300/41A61L 2300/426A61L 31/10A61L 29/16A61L 27/54A61L 31/16A61P 31/00A61P 35/00A61P 9/10A61L 29/085A61L 31/148
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A medical device comprises a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to drugs of Formula (I). The drugs of Formula (I) can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.

Claims

exact text as granted — not AI-modified
1 . A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, said carrier or excipient containing the therapeutic substance 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or prodrug thereof and at least one other therapeutic substance selected from the group consisting of anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, thrombolytic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, and cytostatic drugs. 
     
     
         2 . The medical device of  claim 1 , wherein said anti-proliferative agent is an anti-mitotic agent. 
     
     
         3 . The medical device of  claim 2 , wherein said anti-mitotic agent is selected from the group consisting of vinca alkaloids, anti-mitotic alkylating agents, and anti-mitotic metabolites. 
     
     
         4 . The medical device of  claim 1 , wherein said anti-platelet agent is selected from the group consisting of agents that inhibit adhesion of platelets, agents that inhibit aggregation of platelets, and agents that inhibit activation of platelets. 
     
     
         5 . The medical device of  claim 1 , wherein said anti-inflammatory agent is estradiol. 
     
     
         6 . The medical device of  claim 1 , wherein said anti-inflammatory agent is dexamethasone. 
     
     
         7 . The medical device of  claim 1 , wherein said supporting structure includes a framework in the form of a stent. 
     
     
         8 . The medical device of  claim 1 , wherein said supporting structure is selected from the group consisting of coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. 
     
     
         9 . The medical device of  claim 1 , wherein said supporting structure further comprises a coating, said coating containing said therapeutic substances. 
     
     
         10 . The medical device of  claim 9 , wherein said coating is polymeric. 
     
     
         11 . The medical device of  claim 10 , wherein said polymeric coating is biostable. 
     
     
         12 . The medical device of  claim 10 , wherein said polymeric coating is biodegradable. 
     
     
         13 . The medical device of  claim 1 , wherein said supporting structure includes a polymeric framework containing said therapeutic substances. 
     
     
         14 . The medical device of  claim 13 , wherein said polymeric framework is biodegradable. 
     
     
         15 . The medical device of  claim 1 , wherein said anti-lipaedemic agent is fenofibrate. 
     
     
         16 . The medical device of  claim 1 , wherein said matrix metalloproteinase inhibitor is batimistat.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.